Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1060 related articles for article (PubMed ID: 30853353)

  • 1. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
    Jiang YZ; Ma D; Suo C; Shi J; Xue M; Hu X; Xiao Y; Yu KD; Liu YR; Yu Y; Zheng Y; Li X; Zhang C; Hu P; Zhang J; Hua Q; Zhang J; Hou W; Ren L; Bao D; Li B; Yang J; Yao L; Zuo WJ; Zhao S; Gong Y; Ren YX; Zhao YX; Yang YS; Niu Z; Cao ZG; Stover DG; Verschraegen C; Kaklamani V; Daemen A; Benson JR; Takabe K; Bai F; Li DQ; Wang P; Shi L; Huang W; Shao ZM
    Cancer Cell; 2019 Mar; 35(3):428-440.e5. PubMed ID: 30853353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.
    Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J
    Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
    Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
    Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
    Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF
    Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification.
    Lee M; Yoo TK; Chae BJ; Lee A; Cha YJ; Lee J; Ahn SG; Kang J
    Sci Rep; 2024 May; 14(1):11278. PubMed ID: 38760384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
    Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
    Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
    Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
    Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
    Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.
    Lee YM; Oh MH; Go JH; Han K; Choi SY
    Genes Genomics; 2020 Dec; 42(12):1381-1387. PubMed ID: 33145728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
    Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
    Wang Y; Lin L; Li L; Wen J; Chi Y; Hao R; Dai X; Chen Y; Huang D; Zhou Y; You J; Ye Z; Chen H; Jin L; Chen D; Yang F; Xia E; Ma X; Guo F; Tong Y; Zheng M; Wang O
    Aging (Albany NY); 2021 Apr; 13(8):11860-11876. PubMed ID: 33893247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
    Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ
    Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
    Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
    Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
    Bartels S; van Luttikhuizen JL; Christgen M; Mägel L; Luft A; Hänzelmann S; Lehmann U; Schlegelberger B; Leo F; Steinemann D; Kreipe H
    J Pathol; 2018 Jul; 245(3):373-383. PubMed ID: 29708279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.